Disruptive Mood Dysregulation Disorder

Disruptive mood dysregulation disorder (DMDD) is a childhood condition of extreme irritability, anger, and frequent, intense temper outbursts. DMDD symptoms go beyond a being a “moody” child—children with DMDD experience severe impairment that requires clinical attention.

 

Cluster Number:
Wiki Number: W066
Diagnosis: Disruptive Mood Dysregulation Disorder
US Patients: 1.5% children
World Patients:
Sex Ratio:
Age Onset: Child or adolescent
Brain Area: under-activity of the amygdala at judging other’s anger or sadness; medial front gyrus and anterior cingulate cortex – lower
Symptoms: disproportionate irritable or angry moods or several temper outbursts weekly; poor stress regulation; one year or more
Progression: displays persistent anger against people and objects, often have anxiety and depression in later years
Causes: Brain areas above are important for evaluating and regulating negative emotions; poverty and single-parenthood affect it
Medications: antidepressants, antipsychotics and mood stabilizers
Therapies: None listed.

Youtube Video: Treatment Challenges of Impulse Control

Behavioral Disorder

Amazon or Library Book:

What Were You Thinking?

Amazon or Library Book:

Teach Your Dragon Manners

Click the book to link or buy from Amazon.

Click the book to link or buy from Amazon.

4 CURRENT ARTICLES
FROM PUBMED

The world-wide medical research
reports chosen for each diagnosis 

Clicking each title opens the
PubMed article’s summary-abstract.

  • Factors associated with immune‑related severe adverse events (Review)
    by Zhenzhen Su on November 20, 2024

    Immune checkpoint inhibitors (ICIs) are frequently used in cancer treatment. Despite their clinical benefits, they can also cause a wide range of immune-related adverse events (ir-AEs). The overall incidence of irAEs in cancer patients treated with immunotherapy ranges from 70-90%, while that of immune-related severe adverse events (ir-SAEs) is 10-43%. ir-SAEs pose a significant risk to patient safety as they are extremely frequent and lethal. Due to non-specific manifestations, rapid...

  • Ethical Considerations of Off-Label Prescribing in Disruptive Mood Dysregulation Disorder
    by Harinee Maiyuran on November 14, 2024

    AbstractDisruptive mood dysregulation disorder (DMDD), a relatively new diagnosis in child and adolescent psychiatry that remains without medications approved for its indication, warrants a renewed consideration of the ethics surrounding the off-label use of medications. In the absence of empirical studies, clinicians must work with the best available information regarding treatment, such as case reports demonstrating the success of off-label interventions. Although subject to ethical...

  • Mild behavioural impairment in Parkinson's disease: a systematic review
    by Ruan-Ching Yu on November 11, 2024

    Behavioural symptoms are common manifestations of Parkinson's disease (PD). Early behavioural symptoms characterise mild behavioural impairment (MBI). The prevalence and intensity of MBI in people with PD (PwP) have been studied across various cohorts. However, methodological differences have obscured our understanding of MBI in these individuals. This systematic review examines and synthesises findings from relevant studies, enhancing understanding of the symptoms and implications of MBI in PD....

  • Autonomic response and attachment style in disruptive mood dysregulation disorder
    by Michelle Leal on November 7, 2024

    CONCLUSION: The study demonstrates a potential link between attachment style and altered physiological state in children with DMDD.